Organon Debuts New Analysis of VTAMA® (tapinarof) cream, 1%, Phase 3 Pooled Data Demonstrating Early and Consistent Skin Clearance and Itch Improvement in Atopic Dermatitis Patients Down to 2 Years o
Go back to Organon Debuts New Analysis of VTAMA® (tapinarof) cream, 1%, Phase 3 Pooled Data Demonstrating Early and Consistent Skin Clearance and Itch Improvement in Atopic Dermatitis Patients Down to 2 Years o| (NYSE: OGN) | Delayed: 13.40 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $13.40 | 52 Week High | $8.00 | |||
| Open | $13.40 | 52 Week Low | $8.00 | |||
| Day High | $13.40 | P/E | N/A | |||
| Day Low | $13.40 | EPS | $0.00 | |||
| Volume | 7 | |||||
